<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04508673</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0449</org_study_id>
    <nct_id>NCT04508673</nct_id>
  </id_info>
  <brief_title>Impact of GH Measurements on GHD Diagnosis</brief_title>
  <official_title>Comparative Study of Human Growth Hormone Measurements: Impact on Clinical Interpretation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human growth hormone (hGH) provocation test is an essential tool to assess growth hormone&#xD;
      deficiency in children and young adults. It is important to have a robust and reliable method&#xD;
      to determine the hGH peak of stimulation. This work aimed to compare three common automated&#xD;
      immunoassays for hGH measurements and to assess whether there are still result-related&#xD;
      differences influencing clinical decision.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators analysed GH provocative test of 41 young patients (median age: 12 years)&#xD;
      from Pediatric Department of Montpellier Hospital, (26 boys and 15 girls), admitted for&#xD;
      follow-up or for suspicion of growth hormone deficiency. Serum GH of peak concentrations were&#xD;
      compared using three automated immunoanalyses : COBAS 8000 e602 (ROCHE Diagnostics), IDS-iSYS&#xD;
      (IDS immunodiagnostic systems) and Liaison XL (Diasorin S.A.).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">November 25, 2019</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparative study of human growth hormone measurements</measure>
    <time_frame>1 day</time_frame>
    <description>Comparative study of human growth hormone measurements by using three different automated immunoassays</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stratification of patients based on GH peak secretion</measure>
    <time_frame>1 day</time_frame>
    <description>Stratification of patients based on GH peak secretion</description>
  </secondary_outcome>
  <enrollment type="Actual">41</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GH provocation tst</intervention_name>
    <description>All patients underwent insulin-induced hypoglycaemia stimulation test also called insulin tolerance test (ITT), considered the 'gold standard' test for GHD diagnosis. Following insulin administration by venipuncture (1UI/mL), levels of hGH and glucose were monitored on serum and fluoride tube plasma, respectively, at intervals of 0, 30, 45, 60 and 90 minutes (T0, T30, T45, T60 and T90).</description>
    <other_name>reliquens of serum samples from GH provocation test</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        From April to November 2019, forty-one young patients (26 boys and 15 girls) from the&#xD;
        Paediatric Department of Montpellier Hospital were included in this study. They were mainly&#xD;
        admitted for suspicion (short stature or growth retardation) or follow-up of GHD in pre-and&#xD;
        pubertal age (median age= 12).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age&lt;18 years, admitted for suspicion (short stature or growth retardation) or&#xD;
             follow-up of GHD in pre-and pubertal age&#xD;
&#xD;
          -  patients undergoing insulin-induced hypoglycaemia stimulation test also called insulin&#xD;
             tolerance test (ITT)&#xD;
&#xD;
          -  Exclusion criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Patients undergoing different provocation tests&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuela Lotierzo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH MONTPELLIER</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34290</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 7, 2020</study_first_submitted>
  <study_first_submitted_qc>August 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>growth hormone deficiency</keyword>
  <keyword>immunoanalysis</keyword>
  <keyword>hGH provocation test</keyword>
  <keyword>diagnosis</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

